



PAN MERSEY AREA PRESCRIBING COMMITTEE
PRESCRIBING POLICY STATEMENT
REF: PS141 FINAL
APC BOARD DATE: 27 JUN 2018
PENDING CCG APPROVAL



Pan Mersey
Area Prescribing Committee

TAPENTADOL prolonged release tablets (Palexia® SR)

A
M
B
E
R

The Pan Mersey Area Prescribing Committee recommends
**TAPENTADOL prolonged release tablets (Palexia® SR) for
severe chronic pain in adults only when initiated by chronic
pain specialists or palliative care specialists**

FOLLOWING SPECIALIST INITIATION

The Pan Mersey Area Prescribing Committee (APC) recommends the prescribing of tapentadol prolonged release tablets (Palexia® SR) for severe chronic pain only when initiated by chronic pain specialists or palliative care specialists, and within its licensed indications (the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics).

- > Tapentadol should only be considered as an option, after adequate trials of modified release morphine, **and as an alternative to modified release oxycodone where oxycodone is not considered clinically appropriate.**
- > **The patient should be reviewed by the chronic pain specialist and the tapentadol dose stabilised, with evidence of patient review at that dose, before asking the GP to take over prescribing of tapentadol.**
- > The incidence of gastrointestinal adverse effects is less common with tapentadol than with oxycodone. There is some evidence from the USA that tapentadol has a lower abuse potential than other opioids, but it is not known whether there would be similar picture in the UK, and whether this would be maintained with wider use.
- > Note that the comparative clinical trials assessing tapentadol in chronic pain precluded the use of supplemental/rescue analgesia, only allowing short term paracetamol or NSAIDs for unrelated pain.
- > The Pan Mersey APC **does not currently recommend that [immediate release tapentadol](#) should be used in conjunction with prolonged release tapentadol** as supplemental/rescue analgesia for chronic pain.

Note: Cross-titration (transition from one strong opioid to another) has a RED RAG rating and prescribing of both opioids should be undertaken by the specialist until the first opioid has been stopped.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.

TAPENTADOL prolonged release tablets (Palexia® SR)

<p>EFFECTIVENESS</p> <p>Tapentadol is a dual mode analgesic that inhibits norepinephrine reuptake and has μ-opioid receptor (MOR) agonism.</p> <p>The efficacy of tapentadol SR has been assessed in osteoarthritis, low back and diabetic neuropathic pain in 12-week clinical trials, using dose ranges of 100 - 250 mg twice daily. It was shown to be significantly more effective than placebo in reducing average pain intensity, and was non-inferior to oxycodone modified release (MR) 20 - 50 mg twice daily.</p> <p>There is a lack of long-term efficacy data, and of comparative data with opioid analgesics other than oxycodone¹ and oxycodone/naloxone² (the latter a 12 week open-label, non-inferiority trial).</p>	<p>SAFETY</p> <p>The most common adverse effects of tapentadol (incidence >10%) are dizziness, somnolence, headache, nausea and constipation.³ A pooled analysis of 12-week studies showed significantly reduced incidence of constipation (16.9% vs 33%) and nausea and vomiting (23.3 vs 42.7%) compared to oxycodone. One longer term open label study showed a decreased incidence of GI adverse effects at one year (52.0% vs 64.1% for oxycodone), and an increased incidence of nervous system adverse effects (45.4% vs 39.9% for oxycodone).¹</p> <p>There is some evidence from the United States of low rate of diversion events and low street prices, indicating no substantial diversion and abuse of tapentadol in the 36 months after its introduction.⁴</p> <p>For full details of side-effects and contraindications, see the SPC</p>																
<p>COST</p> <p>Annual costs (Drug Tariff and NHSBSA dm+d browser, September 2017)</p> <p><i>Equivalent to Morphine MR 20mg BD:</i></p> <table border="0"> <tr> <td>Morphine MR (Zomorph®) 20mg BD caps</td> <td>£84</td> </tr> <tr> <td>Oxycodone MR (Oxycontin®) 10mg BD tabs</td> <td>£326</td> </tr> <tr> <td>Oxycodone MR (Longtec®) 10mg BD tabs</td> <td>£163</td> </tr> <tr> <td>Tapentadol SR 50mg BD tabs</td> <td>£325</td> </tr> </table> <p><i>Equivalent to Morphine MR 100mg BD:</i></p> <table border="0"> <tr> <td>Morphine MR (MST Continus®) 100mg BD caps</td> <td>£468</td> </tr> <tr> <td>Oxycodone MR (Oxycontin®) 50mg BD tabs</td> <td>£1,632</td> </tr> <tr> <td>Oxycodone MR (Longtec®) 50mg BD tabs</td> <td>£816</td> </tr> <tr> <td>Tapentadol SR 250mg BD tabs</td> <td>£1,624</td> </tr> </table>	Morphine MR (Zomorph®) 20mg BD caps	£84	Oxycodone MR (Oxycontin®) 10mg BD tabs	£326	Oxycodone MR (Longtec®) 10mg BD tabs	£163	Tapentadol SR 50mg BD tabs	£325	Morphine MR (MST Continus®) 100mg BD caps	£468	Oxycodone MR (Oxycontin®) 50mg BD tabs	£1,632	Oxycodone MR (Longtec®) 50mg BD tabs	£816	Tapentadol SR 250mg BD tabs	£1,624	<p>PATIENT FACTORS</p> <p>Contra-indications include significant respiratory depression, acute or severe bronchial asthma, hypercapnia, paralytic ileus and acute intoxication. Tapentadol is not recommended in severe renal or hepatic impairment or in those under 18 years of age. Caution is needed in moderate hepatic impairment. When combined with a respiratory or CNS depressant drug, the reduction of dose of one or both agents should be considered. Care should be taken when combining tapentadol with mixed μ-opioid agonist/antagonists (like pentazocine, nalbuphine) or partial μ-opioid agonists (like buprenorphine).³</p>
Morphine MR (Zomorph®) 20mg BD caps	£84																
Oxycodone MR (Oxycontin®) 10mg BD tabs	£326																
Oxycodone MR (Longtec®) 10mg BD tabs	£163																
Tapentadol SR 50mg BD tabs	£325																
Morphine MR (MST Continus®) 100mg BD caps	£468																
Oxycodone MR (Oxycontin®) 50mg BD tabs	£1,632																
Oxycodone MR (Longtec®) 50mg BD tabs	£816																
Tapentadol SR 250mg BD tabs	£1,624																
<p>PRESCRIBING INFORMATION</p> <ul style="list-style-type: none"> > Considering the balance of effectiveness, safety, patient factors and cost, the Pan Mersey APC recommends prescribing of tapentadol prolonged release tablets following initiation by chronic pain specialists and only after adequate trials of morphine, or as an alternative to modified release oxycodone where oxycodone is not considered clinically appropriate. > In those not taking opioids, initiate at 50mg BD. In those currently taking opioids, initiate at an appropriate dose based on the current daily dose and equianalgesic dose ratio. The equianalgesic dose ratio of tapentadol to morphine is 2.5:1 and to oxycodone is 5:1.¹ Following initiation, the dose should be titrated on an individual basis, in increments of 50mg tapentadol (as prolonged release tablets) twice daily every 3 days, up to a maximum of 250mg twice daily.³ > Tapentadol is a Schedule 2 Controlled Drug. There are two different formulations of tapentadol (immediate release and prolonged release) which may cause confusion. It is important that the prescriber clearly indicates "prolonged release" in any communication or prescription. Additionally, the similarity between the names and doses of tramadol and tapentadol could cause confusion.¹ 																	
<p>IMPLEMENTATION NOTES</p> <ul style="list-style-type: none"> > It is recommended that only chronic pain specialists initiate tapentadol. Treatment should be reviewed by the specialist and the dose stabilised before asking the GP to take over prescribing. 																	

REFERENCES

1. UKMi New Medicines Profile. Tapentadol prolonged release. 11/03. July 2011
2. Baron R et al. Effectiveness of Tapentadol prolonged release (PR) compared with Oxycodone/Naloxone PR for the management of severe chronic low back pain with a neuropathic component: A randomized, controlled, open-label, Phase 3b/4 Study. Pain Practice. 2015 Jun;15(5): 455-70.
3. Summary of Product Characteristics, Palexia SR, Grunenthal Ltd. Last updated 08-Aug-2016. www.medicines.org.uk (accessed 25/8/17)
4. Dart RC et al. Diversion and Illicit Sale of Extended Release Tapentadol in the United States. Pain Medicine 2016; 17: 1490–1496